Artiva Biotherapeutics Inc ARTV

$4.22 +0.07 (1.69%)

Valuation

Market cap
202,893,000
Revenue TTM
$0
Net income TTM
$-83,870,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
939,900
Avg volume
781,938
Day's range
$4.14 – $4.26
Shares out
48,890,000
Stochastic %K
47%
Beta
2.67
Analysts
Moderate Buy
Price target
$20.75

Price

Company profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis,...

Show more

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 267 4467
Website
https://www.artivabio.com
Address
5505 Morehouse Drive, Suite 100, San Diego, United States

Latest news

Stocktwits

PoseidonCalls Nov 9, 9:55 PM
Short sellers are ruining american small caps and driving companies into bankruptcy!! FMFC has barely 800 watchers on Stocktwits and has been shorted down to only 1.5 million market cap. You could literally buy the ENTIRE company! Webull data stating that FMFC has only 492k shares outstanding and 243k shares float. Watch FMFC here. Making a move 🚀 💎 👀 $ARTV $BTQ ()
0 replies
d_risk Nov 9, 9:26 PM
$ARTV - Artiva Biotherapeutics, Inc. - 10-Q - Updated Risk Factors Artiva says it discontinued AlloNK development and reduced its workforce as part of its strategic review. Peer alert: 312.9% above average. #riskfactors #secfilings 🟢 Added 🟠 Removed https://d-risk.ai/ARTV?filing=kipneprND7d2sElYa66Pj
0 replies
InvestorNOR Nov 7, 10:42 AM
$CMMB $ARTV Imagine how much value it would be for Artiva Biotherapeutics to gain a full pipeline, full restart, with Phase 2 for RA and Phase 3 for PSC? They could have literally readouts a year from now, and full commercialization short time after aquiring Chemomab Therapeutics. Its like the perfect match for Artiva. People should contact IR and the board on Artiva to tell them this is urgent. nebokitug could be locked in a month time, unreachable by Artiva IF merger pass.
0 replies
InvestorNOR Nov 6, 7:47 PM
$ARTV $CMMB Biotech company Evommune, aiming to launch Phase 1 for rheumatoid arthritis, lands $1.1B deal. https://www.techtimes.com/articles/330139/20261105/drug-that-erases-immune-protein-entirely-enters-rheumatoid-arthritis-trials-without-jak-inhibitor.htm
0 replies
TheRagnirLothbrok Nov 5, 1:44 PM
Ticker SCAG had huge news, could go parabolic: Scage Future Enters into Strategic Cooperation Agreement with China Huaye Group SCAG has only 1.3 million shares float - Chinese - Watch it 👀🚀 $NKTR $VWAV $ARTV $JOBY EO
0 replies
InvestorNOR Nov 1, 5:03 PM
$CMMB $ARTV Artiva could literally complete Chemomab`s biggest wish: Run the Phase 3 PSC trial. The one they have been trying to partner since 2024 when full data wasnt available. The one with the smallest competitor pool and the biggest chance at success in shortest amount of time. Artiva have lost a Phase 3 pipeline, they would gain a new Phase 3 pipeline AND a shot at rheumatoid arthritis AND Sclerosis. Two of which they already know and have expertise on. And they have the funds to run all of these trials, without relying on any offerings and dilution to their shareholders. Compared to Scipher, that doesnt even have money to run just 1 single trial, Phase 2 of RA. Which is a graveyard full of dead competitors and many running horses. A pure aquisition here, that would make most sense for both of these companies. Artiva and Chemomab. Maybe Adi Mor could keep her job at Artiva and the board in Chemomab that was originally planned to be fired at Scipher, can help Artiva.
0 replies
Merlintrader Oct 31, 6:41 PM
$ARTV closed the week at $4.19 (-31.9% w/w, -0.9% Friday), below the 50-day SMA ($8.11) and below the 200-day ($8.03). RSI14 20.6. Support $4.00, resistance $7.38 (20-day range, bottom). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/artiva-biotherapeutics-stock-hub/
0 replies
InvestorNOR Oct 30, 3:00 PM
$CMMB $ARTV For those out of the loop: Artiva had to discontinue their entire pipeline after their RA drug failed Phase 2 and there was some deaths to patients. They are now without a pipeline, and is seeking strategic opportunities. They have unlike going concern crappy Scipher Medicine, cash. $300M which was collected to develop RA. And they have expertize in clinical trials, looking to cut 95% of their workforce. They had RA and SSc in the pipeline. That is now dead. nebokitug from Chemomab Therapeutics have Phase 2 for RA soon, they have IND for SSc clear, they have Phase 3 alignment with FDA for PSC, with Orphan status and Fast Track designation. Artiva have the expertise to run trials, they can develop nebokitug, without firing the people. They have $300M cash and can run PSC. Its a match made in heaven. Artiva wants a new IP, Chemomab wants a partner. Leerink have run outreach for Chemomab in 2024, they now run Artiva`s search for a partner. This is perfect.
2 replies